In the first national study to examine survival among liver transplant patients with advanced hepatocellular carcinoma (HCC), researchers found excellent five-year survival results, with a steady improvement over the last decade. Hepatocellular carcinoma, also known as hepatoma, or cancer of the liver, is a common cancer worldwide, with more than one million new cases diagnosed each year and a median life expectancy of six to nine months. Most hepatoma patients have cirrhosis, a risk factor of hepatoma, and are inoperable because of tumor size, location or severity of underlying liver disease. Results of this study will be reported online in the Journal of Clinical Oncology.
"This study shows that we can achieve excellent survival with liver transplantation among patients with hepatoma, confirming similar results reported by single center studies," said Paul J. Thuluvath, MD, senior author and Associate Professor in the Department of Medicine at Johns Hopkins University School of Medicine. "These findings are particularly reassuring for patients with tumors that cannot be surgically removed, which comprise more than 80 % of HCC patients."
The primary objective of the study was to determine survival in an unselected patient population who had liver transplantation for HCC. Using the United Network for Organ Sharing (UNOS) database, researchers collected data on 48,887 patients who underwent liver transplantation in the United States between 1987 and 2001. Patients were excluded if they had undergone multiple organ transplantation, retransplantation, were less than 18 years of age, or lacked survival information.
Of the remaining patients included in the final analysis, 985 had liver transplantation for hepatocellular carcinoma (hepatoma group) and 33,339 patients had liver transplantation for other reasons (control group). Both the hepatoma and control groups were divided into three different five-year time periods: 1987 – 1991, 1992 – 1996, and 1997 – 2001.
Researchers found significant and steady improvement in survival over time among liver transplant patients with HCC, particularly in the last five years. Five-year survival improved from 25.3 percent during 1987-1991 to 47 percent during 1992-1996, and 61.1 percent during 1996-2001.
"Although the survival is low in patients with hepatoma as compared to patients who had transplantation for non-malignant liver conditions, excellent five-year survival rates in patients with HCC suggest that liver transplantation is the treatment of choice in patients with advanced cirrhosis and HCC," said Dr. Thuluvath.
Researchers also wanted to see whether the Milan criteria for selecting HCC patients for liver transplantation, incorporated by many transplant centers as a guideline after a landmark study in 1996, had any indirect effect on patient survival among the 1997-2001 group. Milan criteria require that tumors be less than five centimeters, less than three centimeters if there are one to three tumors, and no invasion of blood vessels or lymph nodes.
Study authors noted that the excellent survival results between 1997 and 2001 may be a result of careful patient selection based on the improved Milan criteria, but cautioned that this finding is based on speculation.
Researchers also noted several limitations to the study. Because they examined a large database and did not have information on detailed staging of individual patients and the actual criteria used at the time of liver transplant, critical information about how patients were selected, tumor size and histology, and the extent of a patients liver disease remains unknown.
In addition, given the prevalence of hepatoma worldwide and the limited supply of organs, researchers pointed to the need for better surveillance, detection and prevention of hepatoma and underlying cirrhosis, and universal HBV vaccination, particularly for countries where organ transplantation is not always an option.
"The outcome of liver transplantation in patients with hepatocellular carcinoma in the US between 1998 and 2001: 5-year survival has improved significantly with time." Paul J. Thuluvath, M.D. et al, Johns Hopkins University School of Medicine, Baltimore, Maryland.
The Journal of Clinical Oncology is the semi-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), the worlds leading professional society representing physicians who treat people with cancer.
ATTRIBUTION TO THE JOURNAL OF CLINICAL ONCOLOGY IS REQUESTED IN ALL NEWS COVERAGE.
For the full text of any JCO article, contact 703-519-1423 or 212-584-5014. The JCO News Digest is also distributed via email. Please let us know if you would like to be added to our email distribution list.
Carrie Housman | Source: EurekAlert!
More articles from Health and Medicine:
Human Stem Cells Predict Efficacy of Alzheimer Drugs
06.12.2013 | Rheinische Friedrich-Wilhelms-Universität Bonn
Recurring memory traces boost long-lasting memories
05.12.2013 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
International team of scientists develops new feedback method for optimizing the laser pulse shapes used in the control of chemical reactions
In many ways, traditional chemical synthesis is similar to cooking. To alter the final product, you can change the ingredients or their ratio, change the method of mixing ingredients, or change the temperature or pressure of the environment of the ingredients.
Like an accomplished chef, chemists have become very skilled ...
A genetic defect protects mice from infection with influenza viruses
A new study published in the scientific journal PLOS Pathogens points out that mice lacking a protein called Tmprss2 are no longer affected by certain flu viruses.
The discovery was made by researchers from the Helmholtz Centre for Infection Research (HZI) in Braunschweig in collaboration with colleagues from Göttingen and ...
The Light: Global study gets underway with online user survey
Light has a fundamental impact on our sense of well-being and performance. In cooperation with Zumtobel, a supplier of lighting solutions, Fraunhofer IAO has launched a global user survey of lighting quality in offices. The objective is to identify the best lighting conditions for a variety of spaces and lighting ...
Quantum entanglement, a perplexing phenomenon of quantum mechanics that Albert Einstein once referred to as “spooky action at a distance,” could be even spookier than Einstein perceived.
Physicists at the University of Washington and Stony Brook University in New York believe the phenomenon might be intrinsically linked with wormholes, hypothetical features of space-time that in popular science fiction can provide a much-faster-than-light shortcut from one part of the universe to another.
But here’s the catch: One couldn’t actually ...
A star is formed when a large cloud of gas and dust condenses and eventually becomes so dense that it collapses into a ball of gas, where the pressure heats the matter, creating a glowing gas ball – a star is born.
New research from the Niels Bohr Institute, among others, shows that a young, newly formed star in the Milky Way had such an explosive growth, that it was initially about 100 times brighter than it is now. The results are published in the scientific journal, Astrophysical Journal Letters.
The young ...
06.12.2013 | Materials Sciences
06.12.2013 | Life Sciences
06.12.2013 | Life Sciences
05.12.2013 | Event News
04.12.2013 | Event News
12.11.2013 | Event News